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Abstract
Purpose The aim of this study was to develop and compare proliposome powder and proliposome tablet formulations for 
drug delivery from a Pari-LC Sprint nebulizer.
Methods Proliposome powders were prepared by the slurry method and sorbitol or mannitol carbohydrate carrier were used 
in a 1:10 and 1:15 w/w lipid phase to carrier ratio. Beclometasone dipropionate (BDP; 2 mol%) was incorporated in the 
lipid phase. Proliposome powders were compressed into tablets, and liposomes were generated from proliposome powders 
or tablets within the nebulizer reservoir for subsequent aerosolization.
Results Comparatively, shorter sputtering times were reported for the tablet formulations (≈ < 2.7±0.45 min), indi-
cating uniform aerosolization. Post-nebulization, liposomes size was larger in the nebulizer reservoir in the range of 
7.79±0.48 µm–9.73±1.53 µm for both powder and tablet formulations as compared to freshly prepared liposomes 
(5.38±0.73 µm–5.85±0.86 µm), suggesting liposome aggregation/fusion in the nebulizer’s reservoir. All formulations exhib-
ited more than 80% mass output regardless of formulation type, but greater BDP proportions (circa 50%) were delivered to 
the Two-stage Impinger when tablet formulations were used. Moreover, the nebulized droplet median size and size distri-
bution were lower for all tablet formulations in comparison to the powder formulations. Proliposome tablet and powdered 
formulations demonstrated the ability to generate vesicles that sustained the release of BDP.
Conclusion Overall, this study showed that proliposome tablets could be disintegrated within a Pari-LC Sprint nebulizer 
to generate inhalable aerosol, with high drug output and hence can be manufactured on large scale to overcome the storage 
problems associated with powder formulations.
Keywords Liposome · Proliposome · Jet-nebulizer · Two-stage impinger · Beclometasone dipropionate · Tablets
Introduction
Aerosol formulations have been employed for pulmonary 
drug delivery to achieve localized treatment for respiratory 
and other immune-mediated diseases (Waldrep. 1998; Godet 
et al. 2017). Moreover, the pulmonary system offers a large 
surface area (82–100  m2), facilitating fast drug absorption to 
the systemic circulation (Khan et al. 2013, 2016). However, 
deep lung deposition, associated with better treatment out-
comes, is challenging. As a consequence, pulmonary formu-
lations and devices are areas of continuous research (Khan 
et al. 2013). Medical nebulizers are devices used to gener-
ate inhalable aerosol, offering deep lung deposition, mostly 
for immediate drug release. Liposomes have been investi-
gated for around five decades as drug carriers in pulmonary 
inhalation. This is due to their ability to entrap hydrophilic 
and hydrophobic drugs (Rojanarat et al. 2012; Kontturi 
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et al. 2019; Subramanian et al. 2016; Bnyan et al. 2020) 
and localize drug action in the lung for prolonged periods 
(Elhissi. 2017). Liposomes may minimize local irritation of 
the lung that may happen because of direct contact between 
the drug and pulmonary epithelium (Girod de Bentzmann 
et al. 1994). Furthermore, inhalation of drug in liposome for-
mulations may provide uniform drug deposition in the lung, 
prolonging drug action via sustained release, and minimize 
local toxicities in the pulmonary epithelium (Darwis and 
Kellaway. 2001; Elhissi 2017)
Nebulization performance of liposomal formulations is 
dependent on an interplay of factors including liposome size, 
formulation composition, nebulizer type and design, and 
nebulization parameters (Bridges and Taylor. 1998; Taylor 
et al. 1990; Elhissi et al. 2015; Niven et al. 1991). Liposomes 
have demonstrated commercialization success in the field 
of inhalation therapy; for example Arikayce® (Insmed, 
NJ, USA) is a nebulizable formulation of amikacin-loaded 
liposomes approved recently by FDA for Mycobacterium 
avium complex lung disease (Shirley. 2019).
However, the poor stability of liposomes during storage is 
still a prominent drawback limiting their shelf life. The insta-
bilities are attributed to oxidation and hydrolysis of phos-
pholipids, causing aggregation and fusion of lipid vesicles 
in an aqueous environment, which may cause leakage of the 
originally entrapped material (Hunt and Tsang. 1981; Khan 
et al. 2018b). Proliposomes are stable formulations that can 
generate liposomes upon hydration with aqueous phase. 
Proliposomes are stable powders of carbohydrate coated or 
mixed with phospholipid, cholesterol and drug using small 
scale production techniques such as modified rotary evapo-
rators (Payne et al. 1986) or large scale methods such as 
fluid-bed coating (Gala et al. 2015) or spray-drying (Omer 
et al. 2018). Alternatively, and as an interest of the present 
research investigation, the slurry-based method can be used 
on small or large scales as shown by our research group 
(Khan et al. 2015). Powders, in general, are susceptible to 
atmospheric factors (moisture, temperature, and humidity) 
and are difficult to store, due to their bulkiness and large 
surface area. Tablets are more convenient for patient admin-
istration and can offer advantages in terms of storage and 
handling when compared to powder formulations. In a recent 
investigation, we capitalized on the advantage of the slurry 
method by developing proliposome tablets having highly 
desirable characteristics (Khan et al. 2018a).
In the present study, we developed Beclometasone 
dipropionate (BDP) proliposome tablets, and investigated 
the ability of the tablets, upon crushing, to generate inhal-
able liposomal aerosol similar to that generated from their 
corresponding powder formulations. We studied the aero-
sol characteristics when sorbitol or mannitol were used as 
carbohydrate carriers in 1:10 or 1:15 w/w lipid to carrier. 
The characteristics of aerosols generated from the tablet 
formulations were studied and compared to their correspond-
ing powder formulations using laser diffraction size analysis. 
The output and output rate of the formulations were also 
reported to evaluate the delivery efficiency. Furthermore, the 
drug deposition profile was evaluated in vitro using inertial 
impaction by employing the Two-stage Impinger (TSI), and 
the drug release profiles of the formulations were also inves-
tigated. This is the first study that proposed anti-asthma pro-
liposome tablets made from simple traditional phospholipid 
and carbohydrate compositions as a system for pulmonary 
delivery via nebulization.
Materials and methods
Materials
Beclometasone dipropionate (BDP), cholesterol, sorbi-
tol (particle size; 250–700 µm) and D-mannitol (particle 
size; < 250 µm) were purchased from Sigma Aldrich, UK. 
Absolute ethanol was bought from Fischer Scientific, UK. 
Soya phosphatidylcholine (SPC) (Lipoid S-100) was kindly 
gifted by Lipoid, Switzerland. Ferric chloride and Ammo-
nium thiocyanate were procured from VWR Scientific, UK. 
A Pari-LC Sprint Air-jet nebulizer fitted with a TurboBoy 
compressor were bought from PARI GmbH, Germany to 
perform all nebulization studies. All materials were used 
as received.
Methods
Preparation of proliposomes via the slurry method
Proliposome powder formulations were prepared via the 
slurry method (Khan et al. 2015, 2018b), using sorbitol or 
mannitol as carbohydrate carriers in 1:10 or 1:15 w/w lipid 
phase to carrier. Particle size of sorbitol ranged from 250 to 
700 µm, whilst mannitol particle size was < 250 µm; both 
powders were used in the size range supplied. SPC and cho-
lesterol were employed in combination as the lipid phase in 
1:1 mol ratio, containing 166.66 mg and 83.34 mg, respec-
tively. BDP was incorporated in 2 mol% (i.e. 4.48 mg) to 
the lipid phase (i.e. 250 mg). The lipid phase constituting 
SPC, cholesterol and BDP were dissolved in absolute etha-
nol (8.26 ml for the 1:10 formulation and 12.01 ml for the 
1:15 formulation (i.e. 333 mg/ml)). Sorbitol or mannitol par-
ticles were placed in a round bottom flask (100 ml) and the 
ethanolic solution was poured onto the carbohydrate carrier 
to form a slurry, ensuring uniform distribution of the lipid 
phase and drug over the carrier particles (the amount of car-
bohydrate carrier was 2.5 g for 1:10 formulations and 3.75 g 
for 1:15 formulations). A rotary evaporator (Buchi Rota-
vapor R-114, Buchi, Switzerland) was utilised to evaporate 
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the ethanol from the slurry, using a vacuum pump (Buchi 
Vac V-501), and by setting up the water bath of the evapo-
rator at 45 °C and the rotation speed at 280 rpm for 2 h. 
Proliposome granules constituting carbohydrate particles 
coated with lipid were then collected and stored at −18 °C 
for conducting subsequent studies.
Scanning electron microscopy (SEM) 
and transmission electron microscopy (TEM)
Surface morphology of proliposome powders was deter-
mined using SEM. For SEM, proliposome powder formu-
lations were transferred to aluminium stubs. Excess pow-
der from the stub was removed via air spray, followed by 
gold coating using a JFC-1200 Fine Coater under vacuum 
for ~ 2 min. Proliposome samples were observed and images 
were captured under SEM (Quanta 200, Czech Republic) at 
20 kV. For TEM, a drop of liposomes suspension (generated 
from proliposome via hydration) and a drop of negative stain 
(1% w/v phosphotungstic acid) were transferred to a carbon 
coated copper grid (400 mesh) (TAAB Laboratories Equip-
ment Ltd., UK). After drying (1 h), liposomes vesicles were 
viewed and photographed using a Philip CM 120 Bio-Twin 
TEM (Philip Electron Optics BV, Netherlands).
Compression of proliposomes via the minipress 
single punch machine
Sorbitol or mannitol-based proliposome granules in either 
1:10 or 1:15 w/w lipid to carrier ratio were compressed into 
round biconvex tablets (6 mm in diameter) using the Riva 
Minipress MII SA single punch machine (Cenova 4018 Ciu-
dadela, Buenos Aires, Argentina). Tablet weights achieved 
for sorbitol-based proliposomes in 1:10 and 1:15 lipid to car-
rier were 90.17±4.30 mg and 91.12±2.66 mg, respectively; 
and for mannitol-based proliposomes were 91.44± 4.21 mg 
and 91.95± 3.95 mg, respectively.
Generation of liposomes from proliposomes
For the purpose of nebulization, 150 mg of proliposome 
powder or tablets formulation (10 tablets were gently crum-
bled in a mortar and pestle) and transferred into the reser-
voir of a Pari-LC Sprint nebulizer (fitted with a TurboBoy 
Compressor; PARI GmbH, Germany). Deionized water 
(DW; 5 ml) was poured in the nebulizer reservoir, followed 
by 3 min of manual shaking to permit tablet disintegration 
and liposome formation. The concentration (i.e. hydration) 
of proliposomes utilised was 30 mg/ml in the nebulizer 
reservoir.
Characterization of liposomes 
before and after nebulization
Liposomes generated from proliposome powders or tablet 
formulations were characterized for size (also referred to 
as volume median diameter; VMD) and size distribution 
(expressed as span) via laser diffraction, using the Malvern 
Mastersizer 2000 (Malvern Instruments LTD., UK). These 
analyses were conducted prior to nebulization (i.e. when 
liposomes were generated from proliposomes powders or 
tablets via hydration) and post-nebulization (i.e. samples 
were collected from the nebulizer reservoir, and the upper 
and lower stages of TSI). The liposome size and size dis-
tribution measurements following completed nebulization 
were compared to those of freshly generated vesicles prior 
to nebulization, in order to study the influence of shearing 
provided by the nebulizer on the integrity of the vesicles.
Stewart assay
The Stewart assay (Stewart 1980) was conducted to deter-
mine the lipid concentration in liposome formulations, so 
that how efficient was the process of coating the lipid onto 
the carrier particles can be evaluated. Individual samples of 
liposome suspension (1 ml) hydrated from sorbitol or man-
nitol-based proliposomes were placed in a glass centrifuge 
tube. Ethanol was added to dissolve the lipid, and samples 
were placed overnight in an oven (i.e. 90 °C). Chloroform 
(2 ml) and ammonium ferrothiocyanate solution (2 ml) 
(ammonium thiocyanate 15.20 g and ferric chloride 13.52 g 
were dissolved in 500 ml deionised water) were added in 
the centrifuge tube. Vortex mixing was conducted for 1 min, 
followed by centrifugation at 300 g for 5 min using a bench 
centrifuge (Jouan B4i, Thermo Electron Corporation, UK). 
The resultant lower chloroform layer containing lipid was 
separated from the upper maroon-coloured iron layer and 
quantified using UV–Visible spectrophotometer at 488 nm 
(Jenway, 7315, Bibby Scientific Ltd, UK).
Nebulizer performance
Nebulizer performance was assessed by examining a num-
ber of variables, including ‘nebulization time’ and ‘sputter-
ing time’. The time required for aerosol generation to start 
becoming erratic and intermittent was determined as the 
nebulization time. Whereas, further tapping of the nebulizer 
leads to continuation of the erratic aerosolization is referred 
to as ‘sputtering’; this duration continued until complete 
cessation of aerosol generation (i.e. till dryness) and was 
reported as ‘sputtering time’. Moreover, complete nebuli-
zation time was referred to the total time of both ‘nebuli-
zation time’ and ‘sputtering time’. Nebulizer performance 
was conducted using sorbitol or mannitol-based proliposome 
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powders or tablets in both 1:10 and 1:15 w/w lipid phase to 
carrier ratio.
Mass output and output rate
After achieving nebulization to ‘dryness’, aerosol mass was 
determined by calculating the percentage difference in mass 
(i.e. weight) between the liposomal formulation in nebulizer 
(150 mg/5 ml), before and after completed nebulization. 
This was conducted for both sorbitol and mannitol-based 
proliposome (in 1:10 and 1:15 w/w lipid to carrier ratios) 
powders and tablets. The percentage mass output was deter-
mined using the following equation;
Output rate was also calculated gravimetrically using the 
following equation:
Nebulizer output efficiency of (BDP)
The output efficiency of the Pari-LC Sprint nebulizer was 
determined by calculating the concentration of BDP col-
lected from the nebulizer reservoir, the upper stage and the 
lower stage of TSI after completed nebulization to ‘dryness’ 
(Section “Nebulizer performance”). BDP concentration was 
analysed and calculated via high performance liquid chro-
matography (HPLC) (Agilent 1200 HPLC instrument, UK). 
A mobile phase constituting methanol and HPLC-grade 
water was used in 75:25 (v/v) with a flow rate of 1.7 ml/
min. The temperature was set at 40 °C, with an injection 
volume of 20 µl and detection wavelength of 239 nm. The 
HPLC instrument employed was set with C-18 column 
(4.6 mm × 150 mm, 5 µm; Agilent Technology, USA). A 
calibration curve for BDP in methanol was constructed in 
the concentration range of 0–50 µg/ml.
Assessment of drug deposition using the (TSI)
The Two-stage Impinger (TSI) was employed as an in vitro 
aerosol deposition model for the nebulized formulation (in 
the form of aerosol). Whilst the lower stage of TSI collects 
particles potentially eligible for ‘peripheral airway’ deposi-
tion (respiratory bronchioles and alveoli), the upper stage of 
the TSI collect particles that would be expected to deposit in 
Mass output(%) =
(
Weight of nebulized formulation
Weight of formulation present in the nebulizer prior to nebulization
)
× 100
Aerosol output rate (mg∕min)
=
(
Weight of nebulized formulation
Complete nebulization time
)
the upper respiratory tract. The aforementioned deposition 
eligibility assumption is based on typical application of 60 l/
min air flow rate across the TSI (the cut-off aerodynamic 
size between the two stages at this flow rate is 6.4 µm) (Hall-
worth and Westmoreland. 1987). During assembly of the 
TSI, the upper and lower stages were loaded with 7 ml and 
30 ml of DW, respectively. Each liposome formulation (i.e. 
sorbitol or mannitol-based proliposome powder and tablets 
for both 1:10 and 1:15 w/w ratios (150 mg/5 ml in DW)) was 
generated in the nebulizer reservoir, prior to nebulization 
(Section “Generation of liposomes from proliposomes”). 
The nebulizer position was positioned with its mouthpiece 
towards the TSI, negative pressure of 60 l/min was applied 
by the vacuum pump and nebulization was started and com-
pleted to ‘dryness’.
Size analysis of nebulized droplets using laser 
diffraction
VMD and span of the aerosol droplets were characterized by 
laser diffraction, using a Malvern SprayTec (Malvern Instru-
ments LTD, UK). Liposomes were generated from powder 
or tablet proliposome formulations (sorbitol or mannitol-
based formulations in 1:10 and 1:15 w/w ratio) in the Pari-
LC Sprint nebulizer (Section “Generation of liposomes from 
proliposomes”). In order to maintain uniform aerosol gener-
ation and measurement, the nebulizer was clamped securely 
at a fixed position of 2.5 cm distance from the laser beam. 
The aerosols generated from the nebulizer were traversed 
through the laser beam with the aid of a vacuum pump (Cop-
ley Scientific, UK). Aerosol droplet size and span values 
were recorded throughout nebulization until the ‘dryness’ 
status was reached (150 mg of proliposome powder or tablet 
were used in 5 ml of DW).
Release study of BDP from liposomes
The release study of BDP from liposomes was conducted 
using dialysis bags (a cut-off MW 3500 Da; this was selected 
based on the pore size, which should between 5–10 times 
larger than the molecular weight of BDP i.e. 521.04 Da) 
followed by HPLC analysis. This method was adopted from 
the release study previously conducted for BDP (Khan et al. 
2018b; Nasr et al. 2014). Hydrated liposomes (i.e. from pro-
liposome powder or proliposome tablets) containing 500 µg 
BDP were sealed in a dialysis bag and placed in 15 ml phos-
phate buffer solution containing 20% of methanol at 25 °C, 
with a continuous stirring at 100 rpm. Methanol was used in 
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order to overcome solubility issues with the drug. Samples 
(200 µl) were withdrawn every hour, and replaced each time 
with the same amount of drug-free media. The BDP release 
study was conducted for 8 h using HPLC. BDP (500 µg), 
dissolved in methanol was also employed for comparison 
purposes and to find out its release profile as a control.
Statistical analysis
Analysis of variance (ANOVA) or Student’s t-tests were 
performed as appropriate for statistical analysis using the 
SPSS software, to determine whether the difference between 
the compared groups was significant. A value of p < 0.05 
was consider an indicator that the difference between the 
compared groups is statistically significant. All experiments 
were conducted in triplicate using three different batches.
Results and discussion
VMD and span analysis of liposomes prior 
and post‑nebulization in TSI
To assess the effect of the nebulization on liposome size, 
measurements were taken before and after nebuliza-
tion. Irrespective of carrier type and lipid concentra-
tion, liposomes generated from proliposome powders 
or proliposome tablets had similar size (p > 0.05). How-
ever, post-nebulization into the TSI, liposome size var-
ied depending upon the compartment of deposition (i.e. 
nebulizer reservoir, upper stage or lower stage). For exam-
ple, compared to upper stage and lower stage, liposomes 
remaining in the nebulizer reservoir were larger in size 
for both tablets (9.32±1.58 µm–9.73±1.53 µm) and pow-
ders (7.79± 0.48–9.67± 0.35 µm) for 1:10 and 1:15 ratios, 
respectively (Table 1). The increase in lipid concentration 
and decrease in temperature of nebulizer contents within 
the jet-nebulizer during nebulization increases the viscos-
ity of formulations and the adherence of atomized primary 
aerosol to the inner walls of the nebulizer (McCallion et al. 
1995; Finlay et al. 2000; Steckel and Eskandar. 2003). It has 
been previously reported that phospholipid may accumu-
late within the nebulizer reservoir during jet-nebulization, 
causing aggregation of liposomes and/or retention of large 
liposomes within the nebulizer (Ferron et al. 1976; Bridges 
and Taylor. 1998). This also agrees with our findings for 
liposomes generated from particulate–based proliposomes 
within air–jet (Elhissi and Taylor. 2005; Elhissi et al. 2012), 
ultrasonic and vibrating–mesh nebulizers (Elhissi and Tay-
lor. 2005).
Moreover, the measured VMD of liposomes in the 
upper stage of the Impinger was independent of formu-
lation type (tablet or powder), carrier type (sorbitol or 
mannitol) or lipid concentration (1:10 or 1:15 lipid to 
Table 1  Volume median 
diameter (VMD) and span 
values for liposomes generated 
from sorbitol or mannitol-based 
proliposome powder and tablets 
in a 1:10 and 1:15 w/w lipid 
phase to carrier ratio by Pari-LC 
Sprint nebulizer before and after 
nebulization
Data are mean ± SD, n = 3; p < 0.05
Proliposome formula-
tions
Before nebulization After nebulization
Liposome (freshly prepared) Nebulizer reservoir Upper stage Lower stage
VMD Powder
Sorbitol 1:10 5.49 ± 1.78 8.33±0.53 5.66±0.56 4.44±0.81
Sorbitol 1:15 5.68 ± 1.55 7.79±0.48 5.19±0.35 3.56±0.21
Mannitol 1:10 5.43 ± 0.74 9.67±0.35 4.62±0.34 3.71±0.25
Mannitol 1:15 5.38 ± 0.73 9.06±1.81 4.59±0.14 3.17±0.62
Tablets
Sorbitol 1:10 5.61±0.84 9.32±1.58 5.78±0.82 3.68±0.58
Sorbitol 1:15 5.85±0.86 9.38±1.15 5.32±0.91 2.14±0.91
Mannitol 1:10 5.47±0.65 9.73±1.53 5.34±0.62 3.21±0.67
Mannitol 1:15 5.39±0.78 9.66±0.36 6.38±0.71 3.63±1.09
Span Powder
Sorbitol 1:10 2.32 ± 0.71 2.58±0.27 3.07±1.26 3.70±0.60
Sorbitol 1:15 2.62 ± 0.75 2.39±0.32 2.33±0.36 2.02±0.39
Mannitol 1:10 3.80 ± 0.79 2.60±0.29 2.40±0.33 3.50±0.80
Mannitol 1:15 3.46 ± 0.97 2.46±0.15 2.16±0.50 2.24±0.21
Tablets
Sorbitol 1:10 2.51 ± 0.61 3.78±1.39 3.63±0.24 1.72±0.64
Sorbitol 1:15 3.62 ± 0.72 2.52±0.84 2.62±1.23 1.18±0.96
annitol 1:10 2.39 ± 0.53 2.58±1.16 1.72±0.87 2.51±1.14
Mannitol 1:15 2.47 ± 0.62 3.12±1.67 3.41±0.71 2.86±1.11
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carrier) (p > 0.05), indicating that nebulized droplets 
with similar size carry liposome vesicles of similar size 
(Table 1). VMD of liposomes in the upper stage of TSI 
were notably similar to the VMD of liposomes prior to 
nebulization, indicating that shearing during nebuliza-
tion had minimal or no effect on size of vesicles deposit-
ing in the Impinger’s upper stage. For all formulations, 
liposomes characterized in the lower stage of the TSI 
were found to have smaller size than those collected 
from the Impinger’s upper stage and nebulizer reservoir 
(Table 1). This demonstrates that liposomes sheared into 
a smaller size within the nebulizer were incorporated into 
smaller droplets that deposited into the lower stage of the 
TSI; this ‘fractionation behaviour’ was observed in our 
previous investigations using liposomes generated from 
ethanol-based proliposomes (Elhissi et al. 2006).
Reduction in liposome size during nebulization was 
attributed to compressed air-driven shearing within the 
nebulizer and impaction of liposomes on the baffles and 
internal walls of the nebulizer, causing fragmentation of 
large liposomes into smaller vesicles (Taylor et al. 1990; 
Saari et al. 1999). Upon examination of span values, no 
significant difference (p > 0.05) was observed between 
proliposome powder and tablet formulations (regardless 
of carrier type, and lipid to carrier ratio) prior to or post-
nebulization (including nebulizer reservoir, upper and 
lower stage of TSI) (Table 1).
Morphology of proliposome formulation via SEM 
and TEM
The surface morphology of coarse carbohydrate carriers 
i.e. sorbitol and mannitol as well as proliposome pow-
ders of sorbitol and mannitol-based formulations using 
both 1:10 and 1:15 w/w lipid phase to carrier ratios were 
examined using scanning electron microscopy (SEM) 
(Fig.  1a–f). Upon examination, it was found that the 
mannitol particles were non-porous in structure, whereas 
sorbitol particles were porous (Fig. 1a–f). Transmission 
electron microscopy (TEM) was used in order to deter-
mine the architecture of liposomes generated via hydra-
tion from proliposome powders and tablets (Fig. 1g, h). 
The generated liposomes from both sorbitol and manni-
tol-based proliposome powders and tablets were similar 
in terms of size and structure and therefore TEM images 
of liposomes hydrated from sorbitol-based proliposome 
powders and sorbitol-based proliposome tablets in a 1:10 
w/w lipid phase to carrier ratios were used (Fig. 1g, h). 
All liposomes were observed to be spherical to oval in 
shape, confirming the successful generation of vesicles 
from proliposome powder and tablet formulations.
Nebulization and sputtering time analysis
Nebulization time to ‘dryness’ was determined for lipo-
some suspension (5 ml) when generated from sorbitol or 
mannitol-based proliposome powder and tablets. Liposomes 
generated from sorbitol or mannitol-based proliposome 
powders in both 1:10 and 1:15 w/w ratios exhibited no sig-
nificant difference (p > 0.05) in terms of nebulization time. 
Moreover, sorbitol-based proliposome tablets at 1:15 ratio 
exhibited a significantly shorter nebulization time (p < 0.05) 
(24.18±0.16 min) compared to sorbitol and mannitol-based 
proliposome powders regardless of lipid concentration in the 
formulation (Fig. 2a). These findings indicate that sorbitol 
was more appropriate as proliposome carrier, if the aim was 
to accomplish nebulization quickly; this might be attributed 
to the greater solubility of sorbitol than mannitol (Bouchard 
et al. 2007), permitting faster formulation disintegration and 
completed nebulization.
Nebulization time for sorbitol-based tablets (1:15 w/w 
ratio) was a significantly shorter (p < 0.05) than that of 
mannitol-based tablets (for both 1:10 and 1:15 w/w ratios; 
31.39±2.66 and 31.36±1.46 min, respectively) (Fig. 2a). The 
difference in nebulization performance might be attributed 
to different solubilities of the carriers or different dispersion 
viscosities resulting from using different carriers. Lipid dis-
persions with lower viscosities may facilitate faster delivery 
of liposomes from nebulizers (Elhissi et al. 2011). Thus, 
formulations having higher lipid contents may contribute 
to generating more viscous liposome formulations, result-
ing in prolonged nebulization times. This assumption was 
ascertained by using the Stewart lipid assay (Stewart. 1980) 
to determine lipid content in each type of carbohydrate car-
rier. Mannitol formulations were found to have higher lipid 
content than sorbitol proliposome formulations (Table 2), 
which may have increased the viscosity of the lipid disper-
sion (Narenji et al. 2017). This is associated with the smaller 
particle size of mannitol (less than 250 µm) than sorbitol 
(250–700 µm), allowing more surface area for lipid deposi-
tion (Fig. 1a–f). Additionally, the decrease in temperature of 
the air-jet nebulizer contents may further elevate the viscos-
ity of the nebulization fluid (Steckel and Eskandar. 2003). 
Higher viscosity may affect nebulization, as explained by 
Finlay et al. (2000), who posed that the higher the viscosity 
the greater the adherence of aerosol droplets to the inner 
walls of the nebulizer, followed by the reduced deflection 
of these droplets into the nebulizer reservoir, greatly pro-
longing the nebulization time (McCallion et al. 1995; Fin-
lay et al. 2000). This was further confirmed by the larger 
measured liposome size for mannitol-based formulations 
in the nebulizer’s reservoir (Table 1), indicating liposome 
aggregation and/or fusion due to increased lipid accumula-
tion within the nebulizer towards the end of nebulization, 
causing prolonged nebulization (Elhissi et al. 2012).
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Sputtering time is identifiable by the sputtering 
behaviour of the nebulizer associated with intermittent 
nebulization (when there is a low volume of suspension 
remaining). Upon direct comparison, no significant dif-
ference (p > 0.05) was found between proliposome tablets 
(i.e. sorbitol and mannitol-based at both ratios). Similar 
results (p > 0.05) were also identified for powder formula-
tions regardless of carrier type and ratio (Fig. 2b). Over-
all, all proliposome powders exhibited longer sputtering 
times when compared with proliposome tablet formula-
tions (Fig. 2b). The exception to this trend was demon-
strated by sorbitol-based proliposome tablets in a 1:15 
w/w ratio, which exhibited a shorter sputtering time (2.42 
± 0.54 min). Trends in sputtering time exhibited by the 
aforementioned sorbitol formulation mirrored nebulization 
time findings (Fig. 2).
Thus, amongst all the formulations prepared via the slurry 
method (powder or tablet), sorbitol-based proliposome 
tablets (particularly a 1:15 w/w ratio) exhibited a notably 
shorter nebulization and sputtering time. This is indicative 
that proliposome formulations manufactured in tablet form, 
are comparatively superior to proliposome powder formula-
tions (i.e. in terms of nebulization rapidity).
Nebulizer output and output rate
Nebulization was performed to ‘dryness’. In general, com-
plete nebulization of liposome dispersion is not achieved, 
and therefore an optimum or 100% mass output is not 
reached; this means that nebulizer at the end of atomization 
will have a fraction of residual components remaining in 
its reservoir (Manca et al. 2012). This is partially attributed 
Fig. 1  SEM images of coarse 
carbohydrate carrier and 
proliposome powder prepared 
with different w/w lipid phase 
to carrier ratios including; (a) 
coarse sorbitol, (b) sorbitol-
based proliposome with 1:10 
w/w, (c) sorbitol-based prolipo-
some with 1:15 w/w, (d) coarse 
mannitol, (e) mannitol-based 
proliposome with 1:10 w/w and, 
(f) mannitol-based proliposome 
with 1:15 w/w. TEM images 
of liposome generated from, 
(g) sorbitol-based prolipo-
some powder 1:10 w/w and, 
(h) sorbitol-based proliposome 
tablets 1:10 w/w ratio. These 
images are typical of three such 
different experiments
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to the presence of large liposomes or liposome aggregates 
(Clay et al. 1983; Elhissi et al. 2006, 2012; Khan et al. 
2016). The total mass of the formulation delivered from the 
nebulizer (i.e. output), and output rate were determined for 
tablet and powder proliposome formulations prepared using 
mannitol or sorbitol carriers.
Sorbitol and mannitol-based powder and tablets exhibited 
similar mass output, regardless of carrier type (Fig. 3a). All 
formulations had output values exceeding 80% (Fig. 3a), 
Fig. 2  Duration of; (a) nebuli-
zation time and, (b) sputtering 
time when liposomes were 
generated from sorbitol or 
mannitol-based proliposome 
powder and tablets in 1:10 and 
1:15 w/w lipid phase to carrier 
ratio in deionised water. Data 
are mean ± SD, n = 3; p < 0.05
Table 2  Stewart assay establishing the amount of lipid phase coated 
on carbohydrate carriers, including: sorbitol or mannitol, with formu-
lations ratios of 1:10 and 1:15 w/w lipid to carrier ratio.
Data mean ± SD, n = 3; p < 0.05
Carrier-based proliposome 
formulations
Percentage lipid concentration (%)
(1:10 w/w) (1:15 w/w)
Sorbitol 1.93 ± 0.14 1.42 ± 0.11
Mannitol 2.21 ± 0.64 1.69 ± 0.29
Fig. 3  Liposome generated 
from sorbitol or mannitol-
based proliposome in deionised 
water in 1:10 and 1:15 w/w 
lipid phase to carrier ratio were 
investigated post-nebulization 
utilising Pari-LC Sprint nebu-
lizer for; (a) aerosol mass output 
(%) and, (b) aerosol output rate 
(mg/min). Data are mean ± SD, 
n = 3; p < 0.05
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which are in concordance to nebulization studies conducted 
for proliposomes prepared using a different proliposome 
technique (Elhissi and Taylor. 2005; Khan et al. 2020a, 
2020b). However, less than 80% mass output was found in 
earlier studies using the Pari-LC nebulizer to deliver tra-
ditional thin-film hydrated liposomes (Bridges and Taylor. 
2000), indicating the advantage of the proliposome technol-
ogy used in this study or the more efficient aerosolization 
offered by the more advanced Pari LC-Sprint nebulizer sys-
tem used in the present investigation.
The output rate was similar for sorbitol and mannitol-
based powder formulations. Amongst all formulations, the 
highest aerosol output rate (180.20 ± 0.31 mg/min) was 
observed for sorbitol-based proliposome tablets (in a 1:15 
w/w lipid phase to carrier ratio). In contrast, the lowest 
output rate (140.92 ± 11.88 mg/min) was determined for 
mannitol-based proliposome tablets (i.e. 1:10 w/w ratio) 
(Fig. 3b). All proliposome powder formulations had simi-
lar output rates. In conclusion, sorbitol-based proliposome 
tablets demonstrated superiority with regard to output and 
output rate of the aerosols. Mannitol-based formulations 
exhibited higher lipid content (confirmed via Stewart assay; 
Table 2), when compared to sorbitol-based formulations. 
Furthermore, higher lipid content of formulations may 
increase viscosity and hence more formulation deposition 
in the internal walls of nebulizer reservoir during nebuliza-
tion, offering poor deflection of formulation in the reservoir, 
also confirmed via longer nebulization time.
The output findings were validated in a subsequent sec-
tion by investigating the drug output characteristics and 
deposition profile in the TSI (Section “Nebulizer output effi-
ciency of BDP using TSI”). It is important here to report the 
fact that gravimetrically determined mass output and output 
rate, although useful for comparing between formulations, 
are not very accurate, owing to solvent evaporation occur-
ring during jet-nebulization, commonly resulting in overes-
timated nebulization output values. Thus, gravimetric out-
put findings were paralleled with drug output determination 
using HPLC, as demonstrated in the subsequent section.
Nebulizer output efficiency of BDP using TSI
Following nebulization into the TSI, BDP concentration in 
the nebulizer reservoir and in the upper and lower stages of 
TSI were determined using HPLC. All formulations, regard-
less of carrier type and lipid concentration, demonstrated 
high drug output; thus, around 50% of BDP was emitted 
from the nebulizer and distributed between the upper and 
lower stages of the TSI. Importantly, proliposome tablets 
exhibited higher BDP output compared to proliposome 
powder formulations, supporting the advantage of com-
pressing the proliposome powders into tablets for subsequent 
nebulization.
Upon looking into the drug distribution between the 
nebulizer reservoir and the Impinger stages, for the powder 
formulations BDP remaining in the nebulizer reached up to 
as high as 62.70% using mannitol carrier (Fig. 4). A similar 
trend was observed for tablets; but with no difference among 
the formulations (p > 0.05) (Fig. 4). Thus, when proliposome 
tablets were used, similar drug output was demonstrated and 
formulation had no effect on drug output. Drug remaining 
in the nebulizer reservoir might be attributed to liposome 
accumulation as a result of aggregation or fusion (Ferron 
et al. 1976; Niven et al. 1991; Bridges and Taylor. 2000).
In the upper and lower stages of TSI, sorbitol (1:15) pro-
liposome powder and tablet formulation elicited a higher 
concentration of BDP depositing in the TSI when compared 
Fig. 4  Beclometasone dipro-
pionate (BDP) concentration 
was determined in the nebulizer 
reservoir, upper and lower 
stages of Two-stage Impinger 
individually for sorbitol or 
mannitol-loaded proliposome 
powder and tablet formulations 
in a 1:10 and 1:15 w/w lipid to 
carrier ratio, post-nebulization. 
Data are mean ± SD, n = 3; 
p < 0.05
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to the other powder and tablet formulations nebulized (Fig. 4 
and Table 3).
The higher total mass output (Fig. 3a) compared to drug 
output (Fig. 4) is attributed to solvent evaporation caused by 
the forced gas during jet-nebulization and/or accumulation 
of BDP with the liposomes in the nebulizer’s reservoir as a 
result of vesicle aggregation/fusion.
Proliposome formulation (i.e. powder or tablet) was 
deemed to have no significant effect upon nebulizer drug 
output efficiency, despite tablets exhibiting marginally 
higher values. Out of the carbohydrate carriers tested, sorb-
itol in a 1:15 w/w ratio was posed to generate liposomes 
that were able to withstand the nebulization process with no 
harm to vesicle integrity.
For tablet formulations, BDP output is higher when com-
pared to powder formulations, and particularly in case of 
sorbitol formulations (Table 3). Again, high viscosity offered 
by mannitol formulation due to smaller particle size and 
more lipid deposition, remained in higher concentration in 
the nebulizer reservoir. Whereas, sorbitol with lower lipid 
concentration demonstrated higher BDP output concentra-
tion. BDP entrapment efficiency (please check supplemen-
tary date (Fig. a)) can be compared with the BDP output 
percentage (Table 3). All proliposome powder and tablet 
formulation exhibited high BDP entrapment than BDP out-
put percentage, which may be related to the sticking of lipid 
content of powder formulations to the punch and die cavity 
during tabletting and hence lower output was determined. 
Moreover, larger size of liposome in the nebulizer reservoir 
post nebulization (Table 1) may further demonstrated t lower 
output percentage of BDP.
VMD and span analysis of aerosol droplets 
via spraytec laser diffraction
In this section, we continued to investigate the characteris-
tics of aerosol. The VMD of nebulized droplets generated 
upon dispersion of proliposome powders was not influenced 
by carrier type or lipid concentration (p > 0.05). Thus, VMD 
values (50% undersize) for aerosols nebulized from hydrated 
proliposome powders were between 4.16 µm and 4.71 µm, 
suggesting that aerosol droplet size was not affected by the 
formulation when the Pari-LC Sprint nebulizer was used 
(Fig. 5a). Furthermore, the size values of droplets generated 
from the hydrated tablets were similar to those of powder 
Table 3  Beclometasone dipropionate (BDP) output (cumulative 
concentration of BDP in the upper and lower stages of Two-stage 
Impinger together in percentage) for sorbitol or mannitol-loaded pro-
liposome formulations in a 1:10 and 1:15 w/w lipid to carrier ratio, 
post-nebulization.
Data are mean ± SD, n = 3; p < 0.05
Proliposome formulations BDP output (%)
Powder Sorbitol (1:10) 45.58 ± 7.89
Sorbitol (1:15) 52.78 ± 7.72
Mannitol (1:10) 37.30 ± 7.68
Mannitol (1:15) 40.38 ± 7.63
Tablets Sorbitol (1:10) 47.62 ± 4.05
Sorbitol (1:15) 54.22 ± 6.64
Mannitol (1:10) 40.08 ± 5.41
Mannitol (1:15) 44.45 ± 6.83
Fig. 5  Representing; (a) volume 
median diameter (VMD) and, 
(b) span of the aerosol droplets 
generated from sorbitol or 
mannitol-based proliposome 
formulations for both 1:10 and 
1:15 w/w lipid to carrier ratios 
using Pari-LC Sprint nebulizer 
via laser diffraction by Malvern 
SprayTec, mean ± SD, n = 3; 
p < 0.05
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formulations (Fig. 5a). Laser diffraction results demonstrated 
aerosol droplet size to be less than 5 µm, indicating potential 
eligibility of aerosols generated from these formulations for 
deposition in “deep lung” (O’Callaghan and Barry. 1997).
Similar to VMD, hydrated tablet formulations exhibited 
a trend for generating aerosols with narrow size distribu-
tion (demonstrated by lower span values) when compared 
to powder formulation in both 1:10 and 1:15 w/w ratio 
(Fig. 5b). However, no significant difference in span values 
were found between powder and tablet formulations, regard-
less of carrier type and lipid to carrier ratio (Fig. 5b). Over-
all, the aerosolization of liposomes generated from the tablet 
formulations (in 1:10 and 1:15 w/w lipid phase to carrier 
ratio) were superior in terms of VMD and span of droplets 
(i.e. tended to have smaller median sizes and narrower size 
distribution), when compared to the corresponding powder 
formulations.
Release study of proliposome powder and tablets
BDP as a control, was released fully (i.e. 100% released) 
within the first 3  h (data not shown). However, over a 
period of 8 h, the maximum release of BDP was found in 
liposomes generated from mannitol-based proliposome 
powder and tablet in both 1:10 and 1:15 w/w formulations 
(i.e. 29.39 ± 1.67% and 27.57 ± 1.87%; 31.98 ± 1.88% and 
29.87 ± 1.85%) (Fig.  6). Comparatively, slower release 
profiles (p < 0.05) of BDP incorporated in liposomes were 
exhibited by sorbitol-based proliposome powder and tab-
let (22.61 ± 1.55% and 19.48 ± 1.62%; 23.45 ± 1.77% and 
21.32 ± 1.63%) (Fig. 6). The crystalline structure of mannitol 
with its large surface area may be attributed to persuade lipid 
distribution over the carbohydrate carrier, whereas sorbitol 
carrier offer porous structure to accommodate phospholipid 
and therefore take longer time to release BDP (Khan et al. 
2018b).
Conclusion
This research aimed to investigate and establish differences 
between proliposome powder and tablet formulations pre-
pared in different ratios using BDP as a model drug. Upon 
investigation, proliposome powder or tablet formulations 
hydrated in nebulizer reservoir (Pari-LC Sprint nebulizer), 
exhibited similar nebulization time, however shorter sput-
tering time was found for all tablet formulations demonstrat-
ing more progressive and consistent aerosolization during 
nebulization. Post-nebulization, VMD of liposomes found 
in the nebulizer reservoir were significantly larger than prior 
to nebulization (for both powder and tablet formulations), 
indicating fusion/aggregation of liposome vesicles forming 
larger liposomes, whereas significantly smaller liposomes 
were found in the lower stage of TSI. Overall, all prolipo-
some tablet formulations demonstrated circa 50% BDP 
delivery into the stages of TSI. Additionally, droplet size 
measurement exhibited a smaller VMD and span values for 
proliposome tablet formulations. In general, proliposome 
tablets also exhibited a sustained release of BDP. Thus, it 
was identified that tabletting of proliposome powders may 
be conducted without detriment to any of the parameters 
investigated. Consequently, due to the advantages of tablet 
formulations i.e. ease in manufacture, dosing, transportation 
and storage and off course large scale manufacturing, it is 
posed that proliposome tablets offer a solution to the draw-
backs associated with proliposome powder formulations.
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Fig. 6  In-vitro release of Beclo-
metasone dipropionate (BDP) 
from liposomes generated from 
sorbitol or mannitol-based 
proliposome powder and tablet 
formulations for both 1:10 and 
1:15 w/w lipid to carrier ratios. 
Data are mean ± SD, n = 3; 
p < 0.05
0
5
10
15
20
25
30
35
40
0 1 2 3 4 5 6 7 8 9
C
um
m
ul
at
iv
e 
am
ou
nt
 o
f B
D
P 
re
le
as
ed
 (%
)
Time (h)
Sorbitol powder 1:10 Sorbitol powder 1:15 Mannitol powder 1:10 Mannitol powder 1:15
Sorbitol tablet 1:10 Sorbitol tablet 1:15 Mannitol tablet 1:10 Mannitol tablet 1:15
 Journal of Pharmaceutical Investigation
1 3
Statement of Human and Animal Rights This article does not contain 
any studies with human and animal subjects performed by any of the 
authors.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
Bnyan R, Cesarini L, Khan I, Roberts M, Ehtezazi T (2020) The 
effect of ethanol evaporation on the properties of inkjet produced 
liposomes. DARU J Pharma Sci 28:271–280
Bouchard A, Hofland GW, Witkamp G-J (2007) Properties of sugar, 
polyol, and polysaccharide water−ethanol solutions. J Chem Eng 
Data 52:1838–1842
Bridges PA, Taylor KMG (1998) Nebulisers for the generation of lipo-
somal aerosols. Int J Pharm 173:117–125
Bridges PA, Taylor KMG (2000) An investigation of some of the fac-
tors influencing the jet nebulisation of liposomes. Int J Pharm 
204:69–79
Clay M, Newman S, Pavia D, Lennard-Jones T (1983) Assessment of 
Jet nebulisers for lung aerosol therapy. The Lancet 322:592–594
Darwis Y, Kellaway IW (2001) Nebulisation of rehydrated freeze-
dried beclomethasone dipropionate liposomes. Int J Pharm 
215:113–121
Elhissi A (2017) Liposomes for pulmonary drug delivery: the role 
of formulation and inhalation device design. Curr Pharm Des 
23:362–372
Elhissi A, Taylor KMG (2005) Delivery of liposomes generated from 
pro liposomes using air-jet, ultrasonic and vibrating-mesh nebulis-
ers. J Drug Del Sci Technol 15:261–265
Elhissi AM, Karnam KK, Danesh-Azari MR, Gill HS, Taylor KM 
(2006) Formulations generated from ethanol-based proli-
posomes for delivery via medical nebulizers. J Pharm Pharmacol 
58:887–894
Elhissi A, Gill H, Ahmed W, Taylor K (2011) Vibrating-mesh nebuliza-
tion of liposomes generated using an ethanol-based proliposome 
technology. J Liposome Res 21:173–180
Elhissi AM, Ahmed W, Taylor KM (2012) Laser diffraction and elec-
tron microscopy studies on inhalable liposomes generated from 
particulate-based proliposomes within a medical nebulizer. J 
Nanosci Nanotechnol 12:6693–6699
Elhissi AM, Dennisin SR, Ahmed W, Taylor KM, Phoenix DA (2015) 
New delivery systems–iposomes for pulmonary delivery of anti-
bacterial drugs. In: David A, Phoenix FH, Dennison SR (eds) 
Novel antimicrobial agents and strategies. Wiley, Hoboken, pp 
387–406
Ferron GA, Kerrebijn KF, Weber J (1976) Properties of aerosols pro-
duced with three nebulizers. Am Rev Respir Dis 114:899–908
Finlay WH, Lange CF, King M, Speert DP (2000) Lung delivery of 
aerosolized dextran. Am J Respir Crit Care Med 161:91–97
Gala RP, Khan I, Elhissi AM, Alhnan MA (2015) A comprehensive 
production method of self-cryoprotected nano-liposome powders. 
Int J Pharm 486:153–158
Girod De Bentzmann S, Bajolet-Laudinat O, Dupuit F, Pierrot D, 
Fuchey C, Plotkowski MC, Puchelle E (1994) Protection of human 
respiratory epithelium from pseudomonas aeruginosa adherence 
by phosphatidylglycerol liposomes. Infect Immun 62:704–708
Godet C, Cateau E, Rammaert B, Grosset M, Le Moal G, Béraud G, 
Martellosio JP, Iriart X, Cadranel J, Roblot F (2017) Nebulized 
liposomal amphotericin b for treatment of pulmonary infection 
caused by hormographiella aspergillata: case report and literature 
review. Mycopathologia 182(7–8):709–713
Hallworth GW, Westmoreland DG (1987) The twin impinger: a simple 
device for assessing the delivery of drugs from metered dose pres-
surized aerosol inhalers. J Pharm Pharmacol 39:966–972
Hunt CA, Tsang S (1981) α-Tocopherol retards autoxidation and 
prolongs the shelf-life of liposomes. Int J Pharm 8:101–110
Khan I, Elhissi A, Shah M, Alhnan MA, Waqar A (2013) Liposome-
based carrier systems and devices used for pulmonary drug 
delivery. In: Davim JP (ed) Biomaterial and medical tribology 
research and development. Woodhead Publishing Limited, Cam-
bridge, UK, pp 395–443
Khan I, Yousaf S, Subramanian S, Korale O, Alhnan MA, Ahmed 
W, Taylor KMG, Elhissi A (2015) Proliposome powders pre-
pared using a slurry method for the generation of beclometasone 
dipropionate liposomes. Int J Pharm 496:342–350
Khan I, Yousaf S, Alhnan MA, Ahmed W, Elhissi A, Jackson MJ 
(2016) Design characteristics of inhaler devices used for pul-
monary delivery of medical aerosols. In: Ahmed W, Jackson MJ 
(eds) Surgical tools and medical devices. Springer International 
Publishing, Cham, pp 573–591
Khan I, Yousaf S, Subramanian S, Albed Alhnan M, Ahmed W, 
Elhissi A (2018a) Proliposome tablets manufactured using a 
slurry-driven lipid-enriched powders: development, characteri-
zation and stability evaluation. Int J Pharm 538:250–262
Khan I, Yousaf S, Subramanian S, Alhnan MA, Ahmed W, Elhissi A 
(2018b) Proliposome powders for the generation of liposomes: 
the influence of carbohydrate carrier and separation conditions 
on crystallinity and entrapment of a model antiasthma steroid. 
AAPS PharmSciTech 19:262–274
Khan I, Apostolou M, Bnyan R, Houacine C, Elhissi A, Yousaf SS 
(2020a) Paclitaxel-loaded micro or nano transfersome formula-
tion into novel tablets for pulmonary drug delivery via nebuliza-
tion. Int J Pharm 575:118919
Khan I, Lau K, Bnyan R, Houacine C, Roberts M, Isreb A, Elhissi A, 
Yousaf S (2020b) A facile and novel approach to manufacture 
paclitaxel-loaded proliposome tablet formulations of micro or 
nano vesicles for nebulization. Pharm Res 37:116
Kontturi L-S, van den Dikkenberg J, Urtti A, Hennink WE, Mastro-
battista E (2019) Light-triggered cellular delivery of oligonu-
cleotides. Pharmaceutics 11:90
Manca M, Sinico C, Maccioni A, Diez O, Fadda A, Manconi M 
(2012) Composition influence on pulmonary delivery of 
rifampicin liposomes. Pharmaceutics 4:590
McCallion ONM, Taylor KMG, Thomas M, Taylor AJ (1995) Nebu-
lization of fluids of different physicochemical properties with 
air-jet and ultrasonic nebulizers. Pharm Res 12:1682–1688
Narenji M, Talaee M, Moghimi H (2017) Effect of bilayer flexibility 
and medium viscosity on separation of liposomes upon stagna-
tion. Iranian Journal of Pharmaceutical Sciences 13:23–34
Nasr M, Najlah M, D’Emanuele A, Elhissi A (2014) Pamam den-
drimers as aerosol drug nanocarriers for pulmonary delivery via 
nebulization. Int J Pharm 461:242–250
Niven RW, Speer M, Schreier H (1991) Nebulization of liposomes. 
II. The effects of size and modeling of solute release profiles. 
Pharm Res 8:217–221
Journal of Pharmaceutical Investigation 
1 3
O’Callaghan C, Barry PW (1997) The science of nebulised drug 
delivery. Thorax 52(Suppl 2):S31–44
Omer HK, Hussein NR, Ferraz A, Najlah M, Ahmed W, Taylor 
KMG, Elhissi AMA (2018) Spray-dried proliposome micropar-
ticles for high-performance aerosol delivery using a monodose 
powder inhaler. AAPS PharmSciTech 19:2434–2448
Payne NI, Timmins P, Ambrose CV, Ward MD, Ridgway F (1986) 
Proliposomes: a novel solution to an old problem. J Pharm Sci 
75:325–329
Rojanarat W, Nakpheng T, Thawithong E, Yanyium N, Srichana T 
(2012) Levofloxacin-proliposomes: opportunities for use in lung 
tuberculosis. Pharmaceutics 4:385
Saari M, Vidgren MT, Koskinen MO, Turjanmaa VMH, Niem-
inen MM (1999) Pulmonary distribution and clearance of two 
beclomethasone liposome formulations in healthy volunteers. 
Int J Pharm 181:1–9
Shirley M (2019) Amikacin liposome inhalation suspension: a 
review in mycobacterium avium complex lung disease. Drugs 
79:555–562
Steckel H, Eskandar F (2003) Factors affecting aerosol performance 
during nebulization with jet and ultrasonic nebulizers. Eur J 
Pharm Sci 19:443–455
Stewart JCM (1980) Colorimetric determination of phospholipids with 
ammonium ferrothiocyanate. Anal Biochem 104(10):14
Subramanian S, Khan I, Korale O, Alhnan MA, Ahmed W, Najlah M, 
Taylor KMG, Elhissi A (2016) A simple approach to predict the 
stability of phospholipid vesicles to nebulization without perform-
ing aerosolization studies. Int J Pharm 502:18–27
Taylor KMG, Taylor G, Kellaway IW, Stevens J (1990) The stability of 
liposomes to nebulisation. Int J Pharm 58:57–61
Waldrep JC (1998) New aerosol drug delivery systems for the treatment 
of immune-mediated pulmonary diseases. Drugs Today (Barc) 
34:549–561
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
